Author(s):
Viol Dhea Kharisma, A. N. M. Ansori, Ahmad Affan Ali Murtadlo, Muhammad Hermawan Widyananda, Emdad Ullah, Sin War Naw, Vikash Jakhmola, Kiran Dobhal, Tarun Parashar, Maksim Rebezov, Rahadian Zainul
Email(s):
rahadianzmsiphd@fmipa.unp.ac.id
DOI:
10.52711/0974-360X.2024.00045 
Address:
Viol Dhea Kharisma1,2, A. N. M. Ansori3, Ahmad Affan Ali Murtadlo2, Muhammad Hermawan Widyananda4, Md. Emdad Ullah5, Sin War Naw6, Vikash Jakhmola7, Kiran Dobhal7, Tarun Parashar7, Maksim Rebezov8,9,10, Rahadian Zainul11,12*
1Department of Biology, Faculty of Science and Technology, Universitas Airlangga, Surabaya, Indonesia.
2Computational Virology Research Unit, Division of Molecular Biology and Genetics, Generasi Biologi Indonesia Foundation, Gresik, Indonesia.
3Professor Nidom Foundation, Surabaya, Indonesia.
4Department of Biology, Faculty of Mathematics and Natural Sciences, Universitas Brawijaya, Malang, Indonesia.
5Department of Chemistry,Mississippi State University, Mississippi, United States.
6Department of Chemistry, Myitkyina University, Myitkyina, Myanmar.
7Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Uttarakhand, Dehradun, India.
8Department of Scientific Research, Russian State Agrarian University – Moscow Timiryazev Agricult
Published In:
Volume - 17,
Issue - 1,
Year - 2024
ABSTRACT:
Infection with a DNA virus called monkeypox virus (MPXV) in humans has been identified in the Congo since 1970. Antiviral drugs are not effective for preventing MPXV infection. MPXV infection cases in Indonesia are very low but MPXV has the potential to become a global pandemic so it is very important to do prevention such as vaccine development. This study aims to construct a B cell epitope-based peptide vaccine candidate in Indonesian MPXV through an in silico approach.The development of the MPXV vaccine can be performed through a computational approach for preliminary studies. In silico-based construction of vaccines using B cell epitopes, antigenicity, allergenicity, docking, and molecular dynamics analysis have been used by researchers and scientists in solving viral infection cases. We recommend Pep A and Pep D as vaccine candidates because they allow recognition by B cells, antigenic peptides, non-allergenic and non-toxin. Peptide vaccine candidate can trigger B-cell activation to produce IgM isotype-specific antibodies through BCR interaction. In summary, the results of this study can be used for an initial study of MPXV vaccine development in Indonesia.
Cite this article:
Viol Dhea Kharisma, A. N. M. Ansori, Ahmad Affan Ali Murtadlo, Muhammad Hermawan Widyananda, Emdad Ullah, Sin War Naw, Vikash Jakhmola, Kiran Dobhal, Tarun Parashar, Maksim Rebezov, Rahadian Zainul. Construction of Peptide Vaccine Candidate Based on β-Cell Epitopes of Indonesian Monkeypox Virus (MPXV) Virulence Protein:A Reverse Vaccinology. Research Journal of Pharmacy and Technology. 2024; 17(1):291-6. doi: 10.52711/0974-360X.2024.00045
Cite(Electronic):
Viol Dhea Kharisma, A. N. M. Ansori, Ahmad Affan Ali Murtadlo, Muhammad Hermawan Widyananda, Emdad Ullah, Sin War Naw, Vikash Jakhmola, Kiran Dobhal, Tarun Parashar, Maksim Rebezov, Rahadian Zainul. Construction of Peptide Vaccine Candidate Based on β-Cell Epitopes of Indonesian Monkeypox Virus (MPXV) Virulence Protein:A Reverse Vaccinology. Research Journal of Pharmacy and Technology. 2024; 17(1):291-6. doi: 10.52711/0974-360X.2024.00045 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2024-17-1-45
REFERENCES:
1. Ladnyj ID, Ziegler P, Kima E. A human infection caused by monkeypox virus in Basankusu Territory, Democratic Republic of the Congo. Bull World Health Organ. 1972; 46(5): 593-7.
2. Hraib M, Jouni S, Albitar MM, Alaidi S, Alshehabi Z. The outbreak of monkeypox 2022: An overview. Ann Med Surg (Lond). 2022; 79: 104069. DOI: 10.1016/j.amsu.2022.104069.
3. Karbalaei M, Keikha M. Overlapping outbreak of COVID-19 and monkeypox in 2022: Warning for immediate preparedness in Iran. Int J Surg. 2022; 105: 106892. DOI: 10.1016/j.ijsu.2022.106892.
4. Sah R, Abdelaal A, Reda A, Katamesh BE, Manirambona E, Abdelmonem H, Mehta R, Rabaan AA, Alhumaid S, Alfouzan WA, Alomar AI, Khamis F, Alofi FS, Aljohani MH, Alfaraj AH, Alfaresi M, Al-Jishi JM, Alsalman J, Alynbiawi A, Almogbel MS, Rodriguez-Morales AJ. Monkeypox and Its Possible Sexual Transmission: Where Are We Now with Its Evidence?. Pathogens. 2022; 11(8): 924. DOI: 10.3390/pathogens11080924.
5. Vivancos R, Anderson C, Blomquist P, Balasegaram S, Bell A, Bishop L, Brown CS, Chow Y, Edeghere O, Florence I, Logan S, Manley P, Crowe W, McAuley A, Shankar AG, Mora-Peris B, Paranthaman K, Prochazka M, Ryan C, Simons D, Vipond R, Byers C, Watkins NA; UKHSA Monkeypox Incident Management team, Welfare W, Whittaker E, Dewsnap C, Wilson A, Young Y, Chand M, Riley S, Hopkins S; Monkeypox Incident Management Team. Community transmission of monkeypox in the United Kingdom, April to May 2022. Euro Surveill. 2022; 27(22): 2200422. DOI: 10.2807/1560-7917.ES.2022.27.22.2200422.
6. Harapan H, Setiawan AM, Yufika A, Anwar S, Wahyuni S, Asrizal FW, Sufri MR, Putra RP, Wijayanti NP, Salwiyadi S, Maulana R, Khusna A, Nusrina I, Shidiq M, Fitriani D, Muharrir M, Husna CA, Yusri F, Maulana R, Utomo PS, Andalas M, Wagner AL, Mudatsir M. Confidence in managing human monkeypox cases in Asia: A cross-sectional survey among general practitioners in Indonesia. Acta Trop. 2020; 206: 105450. DOI: 10.1016/j.actatropica.2020.105450.
7. Chakraborty C, Bhattacharya M, Ranjan Sharma A, Dhama K. Monkeypox virus vaccine evolution and global preparedness for vaccination. Int Immunopharmacol. 2022; 113(Pt A): 109346. DOI: 10.1016/j.intimp.2022.109346.
8. Plotkin S, Robinson JM, Cunningham G, Iqbal R, Larsen S. The complexity and cost of vaccine manufacturing - An overview. Vaccine. 2017; 35(33): 4064-4071. DOI: 10.1016/j.vaccine.2017.06.003.
9. Bhattacharya K, Shamkh IM, Khan MS, Lotfy MM, Nzeyimana JB, Abutayeh RF, Hamdy NM, Hamza D, Chanu NR, Khanal P, Bhattacharjee A, Basalious EB. Multi-Epitope Vaccine Design against Monkeypox Virus via Reverse Vaccinology Method Exploiting Immunoinformatic and Bioinformatic Approaches. Vaccines (Basel). 2022; 10(12): 2010. DOI: 10.3390/vaccines10122010.
10. Khan S, Irfan M, Hameed AR, Ullah A, Abideen SA, Ahmad S, Haq MU, El Bakri Y, Al-Harbi AI, Ali M, Haleem A. Vaccinomics to design a multi-epitope-based vaccine against monkeypox virus using surface-associated proteins. J Biomol Struct Dyn. 2022; 19: 1-10. DOI: 10.1080/07391102.2022.2158942.
11. Fahmi M, Kharisma VD, Ansori ANM, Ito M. Retrieval and Investigation of Data on SARS-CoV-2 and COVID-19 Using Bioinformatics Approach. Adv Exp Med Biol. 2021; 1318: 839-857. DOI: 10.1007/978-3-030-63761-3_47
12. Ansori ANM, Kharishma VD, Muttaqin SS, Antonius Y, Parikesit AA. Genetic Variant of SARS-CoV-2 Isolates in Indonesia: Spike Glycoprotein Gene. J Pure Appl Microbiol. 2020; 14: 971-978. DOI: 10.22207/JPAM.14.SPL1.35
13. Nikolaev DM, Shtyrov AA, Panov MS, Jamal A, Chakchir OB, Kochemirovsky VA, Olivucci M, Ryazantsev MN. A Comparative Study of Modern Homology Modeling Algorithms for Rhodopsin Structure Prediction. ACS Omega. 2018; 3(7): 7555-7566. DOI: 10.1021/acsomega.8b00721.
14. Proboningrat A, Kharisma VD, Ansori ANM, Rahmawati R, Fadholly A, Posa GAV, Sudjarwo SA, Rantam FA, Achmad AB. In silico Study of Natural inhibitors for Human papillomavirus-18 E6 protein. Res J Pharm Technol. 2022; 15(3): 1251-6. doi: 10.52711/0974-360X.2022.00209
15. Kharisma VD, Ansori ANM. Construction of Epitope-Based Peptide Vaccine Against SARS-CoV-2: Immunoinformatics Study. J Pure Appl Microbiol. 2020; 14: 999-1005. DOI: 10.22207/JPAM.14.SPL1.38
16. Ansori ANM, Fadholly A, Kharisma VD, Nugraha AP. Therapeutic potential of avian paramyxovirus serotype 1 for cancer therapy. Biochem Cell Arch. 2020; 20: 2827-2832. DOI: 10.35124/bca.2020.20.S1.2827
17. Kharisma VD, Widodo N, Ansori ANM, Nugraha AP. A vaccine candidate of zika virus (ZIKV) from polyvalent conserved b-cell epitope on viral glycoprotein: In silico approach. Biochem Cell Arch. 2020; 20: 2785-2793. DOI: 10.35124/bca.2020.20.S1.2785
18. Ansori ANM, Fadholly A, Hayaza S, Susilo RJK, Inayatillah B, Winarni D, Husen SA. A Review on Medicinal Properties of Mangosteen (Garcinia mangostana L.). Res J Pharm Techol. 2020; 13(2): 974-982. doi: 10.5958/0974-360X.2020.00182.1
19. Fadholly A, Ansori ANM, Utomo B. Anticancer Effect of Naringin on Human Colon Cancer (WiDr Cells): In Vitro Study. Research Journal of Pharmacy and Technology. 2022; 15(2): 885-888. DOI: 10.52711/0974-360X.2022.00148
20. Husen SA, Wahyuningsih SPA, Ansori ANM, Hayaza S, Susilo RJK, Winarni D, Punnapayak H, Darmanto W. Antioxidant Potency of Okra (Abelmoschus esculentus Moench) Pods Extract on SOD Level and Tissue Glucose Tolerance in Diabetic Mice. Res J Pharm Technol. 2019; 12(12): 5683. doi: 10.5958/0974-360X.2019.00983.1
21. Husen SA, Setyawan MF, Syadzha MF, Susilo RJK, Hayaza S, Ansori ANM, Alamsjah MA, Ilmi ZN, Wulandari PAC, Pudjiastuti P, Awang P, Winarni D. A Novel Therapeutic effects of Sargassum ilicifolium Alginate and Okra (Abelmoschus esculentus) Pods extracts on Open wound healing process in Diabetic Mice. Research J. Pharm. and Tech 2020; 13(6): 2764-2770. DOI: 10.5958/0974-360X.2020.00491.6
22. Wijaya RM, Hafidzhah MA, Kharisma VD, Ansori ANM, Parikesit AP. COVID-19 In Silico Drug with Zingiber officinale Natural Product Compound Library Targeting the Mpro Protein. Makara J Sci. 2021; 25(3): 5. DOI: 10.7454/mss.v25i3.1244
23. Kharisma VD, Kharisma SD, Ansori ANM, Kurniawan HP, Witaningrum AM, Fadholly A, Tacharina MR. Antiretroviral Effect Simulation from Black Tea (Camellia sinensis) via Dual Inhibitors Mechanism in HIV-1 and its Social Perspective in Indonesia. Res J Pharm Technol. 2021; 14(1): 455-460. DOI: 10.5958/0974-360X.2021.00083.4
24. Fadholly A, Ansori ANM, Kharisma VD, Rahmahani J, Tacharina MR. Immunobioinformatics of Rabies Virus in Various Countries of Asia: Glycoprotein Gene. Res J Pharm Technol. 2021; 14(2): 883-886. DOI: 10.5958/0974-360X.2021.00157.8
25. Ansori ANM, Fadholly A, Proboningrat A, Hayaza S, Susilo RJK, Naw SW, Posa GAV, Yusrizal YF, Sibero MT, Sucipto TH, Soegijanto S. In vitro antiviral activity of Pinus merkusii (Pinaceae) stem bark and cone against dengue virus type-2 (DENV-2). Res J Pharm Technol. 2021; 14(7): 3705-8. DOI: 10.52711/0974-360X.2021.00641
26. Ansori ANM, Kharisma VD, Fadholly A, Tacharina MR, Antonius Y, Parikesit AA. Severe Acute Respiratory Syndrome Coronavirus-2 Emergence and Its Treatment with Alternative Medicines: A Review. Research Journal of Pharmacy and Technology 2021; 14(10): 5551-7. DOI: 10.52711/0974-360X.2021.00967
27. Husen SA, Ansori ANM, Hayaza S, Susilo RJK, Zuraidah AA, Winarni D, Punnapayak H, Darmanto W. Therapeutic Effect of Okra (Abelmoschus esculentus Moench) Pods Extract on Streptozotocin-Induced Type-2 Diabetic Mice. Res J Pharm Technol. 2019; 12(8): 3703-3708. DOI: 10.5958/0974-360X.2019.00633.4
28. Ansori ANM, Kharisma VD, Solikhah TI. Medicinal properties of Muntingia calabura L.: A Review. Res J Pharm Technol. 2021; 14(8): 4509-2. doi: 10.52711/0974-360X.2021.00784
29. Yi Z, Ling Y, Zhang X, Chen J, Hu K, Wang Y, Song W, Ying T, Zhang R, Lu H, Yuan Z. Functional mapping of B-cell linear epitopes of SARS-CoV-2 in COVID-19 convalescent population. Emerg Microbes Infect. 2020; 9(1): 1988-1996. DOI: 10.1080/22221751.2020.1815591.
30. Fadholly A, Ansori ANM, Sucipto TH. An overview of naringin: Potential anticancer compound of citrus fruits. Research Journal of Pharmacy and Technology. 2020; 13(11): 5613-5619. DOI: 10.5958/0974-360X.2020.00979.8